Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song(Peking University), Jun Zhu(Peking University Cancer Hospital), Kaiyang Ding(Anhui Provincial Hospital), Huilai Zhang(Tianjin Medical University Cancer Institute and Hospital), Pamela B. Allen(Emory University), Yue-Rong Shuang(Jiangxi Provincial Cancer Hospital), Dok Hyun Yoon(Asan Medical Center), Liqun Zou(Sichuan University), Jianqiu Wu(Jiangsu Cancer Hospital), Zhenfan Yang, Haiyan Yang(Chinese Academy of Sciences), Keshu Zhou(Henan Cancer Hospital), Qingqing Cai(Sun Yat-sen University), Weili Zhao(Shanghai Institute of Hematology), Fernando Roncolato(St George Hospital), Miles Prince(Epworth Hospital), Hui Zhou(Hunan Cancer Hospital), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Luis Malpica(The University of Texas MD Anderson Cancer Center), Lie Lin(Hainan General Hospital), Sujun Gao(First Hospital of Jilin University), Hui Liu(Sichuan University), Wenyu Li(Guangdong Provincial People's Hospital), Yao Liu(Chongqing University), Liling Zhang(Huazhong University of Science and Technology), Zhimin Zhai(Anhui Medical University), Fei Li(Anhui University), Jie Jin(First Affiliated Hospital Zhejiang University), Yaming Xi(First Hospital of Lanzhou University), Youngil Koh(Seoul National University Hospital), Zengjun Li(Shandong First Medical University), Won-Seog Kim(Samsung Medical Center), Meifang Zheng
The Lancet Oncology
December 9, 2023
10.1016/s1470-2045(23)00589-2
Cited by 55

Related Papers

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403